Zacks Research downgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a strong-buy rating to a hold rating in a research note released on Thursday,Zacks reports.
BDX has been the subject of a number of other research reports. UBS Group started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Barclays upped their target price on Becton, Dickinson and Company from $165.00 to $195.00 and gave the company an “underweight” rating in a research report on Tuesday, November 10th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup upped their price target on shares of Becton, Dickinson and Company from $208.00 to $241.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $197.47.
Get Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same period in the prior year, the business posted $3.96 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.6% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 101.45%.
Insider Activity at Becton, Dickinson and Company
In related news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of Becton, Dickinson and Company stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $23,134,230. The trade was a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,310 shares of company stock worth $688,650 in the last 90 days. 0.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Defiance ETFs LLC acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $224,000. Kestra Advisory Services LLC increased its stake in shares of Becton, Dickinson and Company by 616.1% during the third quarter. Kestra Advisory Services LLC now owns 89,336 shares of the medical instruments supplier’s stock valued at $15,991,000 after acquiring an additional 76,861 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $1,002,000. Auxier Asset Management LLC raised its holdings in Becton, Dickinson and Company by 1.1% during the third quarter. Auxier Asset Management LLC now owns 17,919 shares of the medical instruments supplier’s stock worth $3,208,000 after purchasing an additional 200 shares in the last quarter. Finally, Innovator Capital Management LLC bought a new stake in Becton, Dickinson and Company during the third quarter worth approximately $2,709,000. 86.97% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
